Sodium Channel Blocker Tolerance as a Metric for Disease Modification in Dravet Syndrome Authors: Koichiro Yuji, Wakako Yuji Published: 2026 The recent publication by Laux et al. reporting the phase 1‐2a trial results of zorevunersen marks a pivotal moment in the management of Dravet syndrome. By utilizing an antisense oligonucleotide to upregulate Nav1.1 expression from the wild‐type SCN1A allele, the therapeutic paradigm is finally shifting from symptomatic seizure suppression toward addressing the root genetic etiology. While the reported reductions in convulsive seizures are highly encouraging, evaluating zorevunersen exclusively as an adjunctive therapy alongside standard, non‐sodium‐channel‐blocking antiseizure medications forecloses the most consequential test of genuine disease modification [1]. Dravet syndrome is fundamentally driven by SCN1A haploinsufficiency, which selectively impairs Nav1.1 channels in GABAergic inhibitory interneurons. Consequently, sodium channel blockers (SCBs) are strictly contraindicated; they further diminish interneuron excitability, precipitate severe seizure exacerbations, and independently impair cognitive outcomes [2, 3]. However, if sustained target engagement by zorevunersen genuinely restores Nav1.1 to physiological levels, the specific molecular deficit that renders SCBs harmful should, in principle, be reversed [1]. Demonstrating that a targeted therapy safely restores tolerance to SCBs would represent the ultimate, irrefutable proof of true disease modification. Unfortunately, the clinical development program for zorevunersen—including the forthcoming phase 3 EMPEROR trial (NCT06872125)—perpetuates the strict exclusion of patients receiving maintenance SCBs. By avoiding this specific pharmacological challenge, the field risks embedding a critical knowledge gap permanently into clinical practice, leaving it ambiguous whether the underlying neuropharmacological phenotype has been truly normalized or if seizures are merely being suppressed. While intentionally administering contraindicated drugs poses obvious ethical challenges in trials, real‐world clinical practice offers unique opportunities for insight. For instance, as established by the International Consensus Guidelines [2], intravenous phenytoin remains an established emergency option for the management of status epilepticus in Dravet syndrome. The extension protocols for zorevunersen appropriately permitted such short‐term emergency SCB use. Analyzing these incidental exposures—specifically asking whether paradoxical seizure exacerbation was notably absent in zorevunersen‐treated patients who received emergency SCBs—could provide the first clinical evidence of phenotypic reversal. This distinction extends far beyond academic pathophysiology. In many resource‐constrained settings globally, SCBs remain the most consistently accessible and affordable antiseizure medications. Unlocking tolerance to the most widely prescribed antiepileptic drug class would radically alter the global trajectory of Dravet syndrome and liberate patients from highly complex, specialized polypharmacy. We urge investigators of ongoing and future SCN1A‐targeted gene therapies to actively leverage these pharmacological paradoxes, transforming a historic contraindication into the definitive biomarker of therapeutic success. Author Contributions Koichiro Yuji: conceptualization, methodology, supervision, project administration, investigation, writing – original draft. Wakako Yuji: writing – review and editing, methodology, conceptualization, writing – original draft. Funding The authors have nothing to report. Conflicts of Interest Dr. Koichiro Yuji reports institutional support from Tokyu Land Corporation for a Social Cooperation Research Department at the University of Tokyo and personal fees from DeNA Co. Ltd.; both are outside the submitted work. The other author declares no conflicts of interest. Data Availability Statement Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study.